JPWO2020106916A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020106916A5
JPWO2020106916A5 JP2021529002A JP2021529002A JPWO2020106916A5 JP WO2020106916 A5 JPWO2020106916 A5 JP WO2020106916A5 JP 2021529002 A JP2021529002 A JP 2021529002A JP 2021529002 A JP2021529002 A JP 2021529002A JP WO2020106916 A5 JPWO2020106916 A5 JP WO2020106916A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
seq
nos
aav vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508182A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062531 external-priority patent/WO2020106916A1/en
Publication of JP2022508182A publication Critical patent/JP2022508182A/ja
Publication of JPWO2020106916A5 publication Critical patent/JPWO2020106916A5/ja
Pending legal-status Critical Current

Links

JP2021529002A 2018-11-21 2019-11-21 組換えウイルスベクター及びそれの産生のための核酸 Pending JP2022508182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770202P 2018-11-21 2018-11-21
US62/770,202 2018-11-21
PCT/US2019/062531 WO2020106916A1 (en) 2018-11-21 2019-11-21 Recombinant viral vectors and nucleic acids for producing the same

Publications (2)

Publication Number Publication Date
JP2022508182A JP2022508182A (ja) 2022-01-19
JPWO2020106916A5 true JPWO2020106916A5 (ru) 2022-11-30

Family

ID=70773595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529002A Pending JP2022508182A (ja) 2018-11-21 2019-11-21 組換えウイルスベクター及びそれの産生のための核酸

Country Status (20)

Country Link
US (1) US20210324418A1 (ru)
EP (1) EP3883954A4 (ru)
JP (1) JP2022508182A (ru)
KR (1) KR20210103469A (ru)
CN (1) CN113302201A (ru)
AR (1) AR117145A1 (ru)
AU (1) AU2019385506A1 (ru)
BR (1) BR112021009733A2 (ru)
CA (1) CA3120289A1 (ru)
CL (1) CL2021001327A1 (ru)
CO (1) CO2021008120A2 (ru)
EA (1) EA202191418A1 (ru)
EC (1) ECSP21044840A (ru)
IL (1) IL283344A (ru)
MX (1) MX2021005997A (ru)
PE (1) PE20211419A1 (ru)
PH (1) PH12021551155A1 (ru)
SG (1) SG11202105326WA (ru)
TW (1) TW202039533A (ru)
WO (1) WO2020106916A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107686842A (zh) * 2016-08-03 2018-02-13 南京大学 一种靶多核苷酸编辑方法及其应用
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
IL292297A (en) 2019-10-17 2022-06-01 Stridebio Inc Adeno-associated viral vectors for the treatment of Niemann-Pick type c disease
US20220010332A1 (en) * 2020-07-08 2022-01-13 Neuracle Genetics Inc. Intron fragments
US20230285596A1 (en) * 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
US20220098255A1 (en) * 2020-09-29 2022-03-31 NeuExcell Therapeutics Inc. Neurod1 combination vector
CA3197321A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Neurod1 vector
WO2022072309A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Ascl1 vector
WO2023221942A1 (en) * 2022-05-16 2023-11-23 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating glutaric aciduria type i
WO2023240162A1 (en) * 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Aav vectors for gene editing
WO2024074143A1 (en) * 2022-10-08 2024-04-11 Lingyi Biotech Co., Ltd. Construct for enhancing gene expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
US20160256571A1 (en) * 2013-09-30 2016-09-08 Sanofi Invention
CA2970730A1 (en) * 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2016150964A1 (en) * 2015-03-23 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
IL296365A (en) * 2015-05-16 2022-11-01 Genzyme Corp Genetic editing of deep intronic mutations
KR102200642B1 (ko) * 2015-11-05 2021-01-12 뱀부 테라퓨틱스 인코포레이티드 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
AU2016372035B2 (en) * 2015-12-15 2023-03-30 Genzyme Corporation Adeno-associated viral vectors for treating mucolipidosis type ii
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks

Similar Documents

Publication Publication Date Title
JP7303287B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2021106619A5 (ru)
RU2021102893A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2019116492A5 (ru)
JP2021019591A5 (ru)
JP2021087431A5 (ru)
JP2018522529A5 (ru)
TW202005978A (zh) 新穎肝靶向腺相關病毒載體
JP2021003120A5 (ru)
US20040087028A1 (en) Ecdysone-inducible adeno-associated virus expression vectors
JP7162021B2 (ja) 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
JPWO2020106916A5 (ru)
US20020076754A1 (en) Overcoming AAV vector size limitation through viral DNA hetero-dimerization
JP2017529395A5 (ru)
WO2020208032A1 (en) Hybrid promoters for muscle expression
CA3122319A1 (en) Expression cassettes for gene therapy vectors
JPWO2021067448A5 (ru)
JPWO2021076911A5 (ru)
JPWO2021014428A5 (ru)
JPWO2020069339A5 (ru)
JPWO2019222411A5 (ru)
JPWO2021050614A5 (ru)
US20240067678A1 (en) Adeno-associated virus capsids and vectors
JPWO2019200286A5 (ru)
RU2022111695A (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение